19.54 USD
+2.56 (+15.08%)
19.4 USD
-0.14 (-0.72%)
We assign a fundamental rating of 2 out of 10 to PTN. PTN was compared to 534 industry peers in the Biotechnology industry. Both the profitability and financial health of PTN have multiple concerns. PTN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
PTN had negative earnings in the past year.
In the past year PTN has reported a negative cash flow from operations.
In the past 5 years PTN always reported negative net income.
In the past 5 years PTN reported 4 times negative operating cash flow.
1.2 Ratios
PTN has a Return On Assets of -625.34%. This is amonst the worse of the industry: PTN underperforms 97.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -625.34% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-176.98%
ROA(5y)-121.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of PTN (1255.00%) is better than 100.00% of its industry peers.
PTN's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for PTN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 1255% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.23%
GM growth 5YN/A
2. Health
2.1 Basic Checks
PTN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PTN has more shares outstanding
Compared to 5 years ago, PTN has more shares outstanding
Compared to 1 year ago, PTN has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -169.70, we must say that PTN is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of PTN (-169.70) is worse than 97.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -169.7 |
ROIC/WACCN/A
WACC8.67%
2.3 Liquidity
A Current Ratio of 0.38 indicates that PTN may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.38, PTN is doing worse than 93.63% of the companies in the same industry.
PTN has a Quick Ratio of 0.38. This is a bad value and indicates that PTN is not financially healthy enough and could expect problems in meeting its short term obligations.
PTN's Quick ratio of 0.38 is on the low side compared to the rest of the industry. PTN is outperformed by 93.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.38 | ||
| Quick Ratio | 0.38 |
3. Growth
3.1 Past
PTN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -109.14%.
PTN shows a decrease in Revenue. In the last year, the revenue decreased by -7.42%.
PTN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -40.52% yearly.
EPS 1Y (TTM)-109.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.04%
Revenue 1Y (TTM)-7.42%
Revenue growth 3YN/A
Revenue growth 5Y-40.52%
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, PTN will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.65% on average per year.
PTN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 162.67% yearly.
EPS Next Y98.1%
EPS Next 2Y41.88%
EPS Next 3Y27.03%
EPS Next 5Y15.65%
Revenue Next Year-100%
Revenue Next 2Y325.2%
Revenue Next 3Y164.44%
Revenue Next 5Y162.67%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PTN. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 28.45, which means the current valuation is very expensive for PTN.
PTN's Price/Forward Earnings ratio is rather cheap when compared to the industry. PTN is cheaper than 91.57% of the companies in the same industry.
PTN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 36.56, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 28.45 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PTN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PTN's earnings are expected to grow with 27.03% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.88%
EPS Next 3Y27.03%
5. Dividend
5.1 Amount
No dividends for PTN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
19.54
+2.56 (+15.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.86%
Inst Owner Change-10.33%
Ins Owners0.75%
Ins Owner Change0.19%
Market Cap34.98M
Revenue(TTM)4.49M
Net Income(TTM)-26.95M
Analysts80
Price Target7.14 (-63.46%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)48%
Min EPS beat(2)24.29%
Max EPS beat(2)71.71%
EPS beat(4)3
Avg EPS beat(4)25.29%
Min EPS beat(4)-5.65%
Max EPS beat(4)71.71%
EPS beat(8)3
Avg EPS beat(8)-26.04%
EPS beat(12)6
Avg EPS beat(12)-12.52%
EPS beat(16)8
Avg EPS beat(16)-16.16%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-4900%
EPS NQ rev (3m)-4900%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 28.45 | ||
| P/S | 99.93 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-59.5
EYN/A
EPS(NY)0.69
Fwd EY3.51%
FCF(TTM)-15.05
FCFYN/A
OCF(TTM)-15.05
OCFYN/A
SpS0.2
BVpS-3.56
TBVpS-3.56
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -625.34% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 1255% | ||
| FCFM | N/A |
ROA(3y)-176.98%
ROA(5y)-121.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.23%
GM growth 5YN/A
F-Score3
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1.53% | ||
| Cap/Sales | 1.4% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.38 | ||
| Quick Ratio | 0.38 | ||
| Altman-Z | -169.7 |
F-Score3
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)120.27%
Cap/Depr(5y)96.16%
Cap/Sales(3y)9.17%
Cap/Sales(5y)16.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-109.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.04%
EPS Next Y98.1%
EPS Next 2Y41.88%
EPS Next 3Y27.03%
EPS Next 5Y15.65%
Revenue 1Y (TTM)-7.42%
Revenue growth 3YN/A
Revenue growth 5Y-40.52%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y325.2%
Revenue Next 3Y164.44%
Revenue Next 5Y162.67%
EBIT growth 1Y1.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.47%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y22.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.15%
OCF growth 3YN/A
OCF growth 5YN/A
PALATIN TECHNOLOGIES INC / PTN FAQ
What is the fundamental rating for PTN stock?
ChartMill assigns a fundamental rating of 2 / 10 to PTN.
Can you provide the valuation status for PALATIN TECHNOLOGIES INC?
ChartMill assigns a valuation rating of 3 / 10 to PALATIN TECHNOLOGIES INC (PTN). This can be considered as Overvalued.
Can you provide the profitability details for PALATIN TECHNOLOGIES INC?
PALATIN TECHNOLOGIES INC (PTN) has a profitability rating of 1 / 10.
What is the financial health of PALATIN TECHNOLOGIES INC (PTN) stock?
The financial health rating of PALATIN TECHNOLOGIES INC (PTN) is 0 / 10.